Jonathan Birchall - 20 May 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role
Chief Commercial Officer
Signature
/s/ John P. Sharp, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
20 May 2022
Net transactions value
+$13,626
Form type
4
Filing time
24 May 2022, 17:13:06 UTC
Previous filing
28 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHASQ Common Stock Award $13,626 +20,000 $0.6813* 20,000 20 May 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") in a transaction that is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 In accordance with the ESPP provisions, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 20, 2022.